Safety data on AstraZeneca anemia drug points to potential use in dialysis

Share this post

AstraZeneca said on Friday that safety data on roxadustat underpinned the British drugmaker’s hopes for the anemia drug to become a standard treatment for patients with kidney disease.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply